Taiwan Bio Therapeutics
Investors
  1. Home
  2. Investors
  3. Corporate Governance
  4. Committees
  5. Audit Committee
Corporate Governance
Board of Directors Committees Corporate Governance Officer Major Internal Policies
Financials
Monthly Revenue Financial Reports
Shareholder Services
Major Shareholders Meeting Information Stakeholder Contact Prospectuses Material Information Dividend and Stock
Investor Conference
Interested Parties
Audit Committee Compensation Committee
Committee members

Title Name
Chairperson Amy Chen
Member C. H Liu
Member Eric Wu


The term of the current committee members: 9 June 2024 to 18 June 2027.
The Operation of the Audit Committee

The committee is composed of all independent directors, with no fewer than three members, one of whom shall serve as the convener. At least one member must have expertise in accounting or finance.

The term of office for independent directors on the committee is three years, with the possibility of re-election. For detailed regulations, please refer to the Audit Committee's organizational charter.

Audit Committee Resolution
Date Resolution
May 12
  • Approval of the Company's financial report for the first quarter of 2025.
  • Approval of the acquisition of 100% equity in Tract Therapeutics, Inc. 
  • Approval of the establishment of a new U.S. subsidiary and sub-subsidiary.
  • Approval of the change in the Company's chief auditor.
  • Approval of the list of employees eligible for the 2023 employee stock options and the number of options granted.
Mar. 12
  1.    Approval of the engagement of Ernst & Young and its affiliates for the provision of non-assurance services.
  2.    Approval of the 2024 Business Report and Financial Statements.
  3.    Approval of the appointment of Ernst & Young as the auditor for the Company's 2025 financial and tax  statements, along with the assessment of the auditors’ independence and qualifications.
  • Approval of the deficit compensation plan for 2024.
  • Approval of the revision of the Company's internal control system and the definition of the scope of entry-level employees.
  • Approval of the discontinuation of the private placement of common shares through cash capital increase approved at the 2024 Annual General Shareholders' Meeting.
  • Approval of a new private placement of common shares through cash capital increase in 2025.
  • Approval of the convening of the 2025 Annual General Shareholders' Meeting.
  • Approval of capital injection into the Company’s U.S. subsidiary, PhiBio Therapeutics Inc.